Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- Feb 12 2018 Adamis Pharmaceuticals Announces FDA Acceptance for Review for the Supplemental New Drug Application of Its Low Dose Symjepi Product Candidate
- Dec 6 2017 US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses
- Dec 4 2017 Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose
- Dec 1 2017 Adamis Pharmaceuticals Announces Presentation of Results of a Human Factors Study Conducted With Its Newly Approved Epinephrine Pre-filled Syringe at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy Organization